Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial

British Medical Journal

Volumn 321, Issue 7274, 2000, Pages 1445-1449

  Wilcock, G K ^a   Lilienfeld, S ^b   Gaens, E ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; GALANTAMINE; PLACEBO;

ADULT; AGED; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; CAREGIVER; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; GENOTYPE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 0034627263     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.321.7274.1445     Document Type: Article

References (28)

1. The cholinergic hypothesis of geriatric memory dysfunction
2. The treatment of Alzheimer's disease
3. Cholinesterase inhibitors in the treatment of Alzheimer's disease: A comparison of tolerability and pharmacology
4. New therapeutic approaches to Alzheimer's disease
5. Do we have drags for dementia?
6. Effectiveness of rivastigmine in Alzheimer's disease
7. Effect of gender and apolipoprotein E genotype on response to acetylcholinesterase therapy in Alzheimer's disease
8. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease
9. Pharmacological evaluation of novel Alzheimer's disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine
10. Characteristics of galanthamine as a reversible inhibitor of cholinesterase
11. Properties of neuronal nicotinic acetylcholine receptors: Pharmacological characterization and modulation of synaptic function
12. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS/ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease
13. 'Mini-mental state.' A practical method for grading the cognitive state of patients for the clinician
14. A new rating scale for Alzheimer's disease
15. Apolipoprotein E genotyping by one-stage PCR
16. Validity and reliability of the Alzheimer's disease cooperative study-clinical global impression of charge
17. Development of a functional measure for persons with Alzheimer's disease: The disability assessment for dementia
18. On the combination of independent two sample tests of Wilcoxon
19. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: The MALT study
20. The eficacy and safety of donepezil in patients with Alzheimer's disease: Results of US multicentre, randomized, double-blind, placebo-controlled trial
21. Donepezil improves cognition and global function in Alzheimer disease
22. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
23. The effects of donepezil in Alzheimer's disease - Results from a multinational trial
24. A randomized trial evaluating the afficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
25. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
26. Apolipoprotein E and Alzheimer's disease: A review of recent studies
27. Metrifonate treatment of AD: Influence of APOE genotype
28. A 5-month, randomized, piacebo-controlled study of galantamine in AD